Anthony Richardson

Title: Anthony Richardson: Innovator in Thromboembolic Disease Therapies

Introduction

Anthony Richardson is a notable inventor based in Oxfordshire, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit Factor XIa, which plays a crucial role in thromboembolic diseases. With a total of 2 patents to his name, Richardson's work is paving the way for innovative therapies.

Latest Patents

Richardson's latest patents include two key inventions. The first patent, titled "Pyrimidinone and its derivatives inhibiting factor XIa," presents compounds of the general formula (I), their salts, N-oxides, solvates, and prodrugs. These compounds are designed to inhibit Factor XIa, making them useful in the prevention and therapy of thromboembolic diseases. The second patent, "Pyridinone and pyrimidinone derivatives as factor XIa inhibitors," similarly provides compounds of the general formula (I) with the same therapeutic applications.

Career Highlights

Anthony Richardson is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on developing effective treatments for conditions related to blood clotting and thromboembolic events.

Collaborations

Richardson collaborates with esteemed colleagues, including Steve Courtney and Chris Yarnold. Their combined expertise enhances the research and development efforts within their field.

Conclusion

Anthony Richardson's contributions to the pharmaceutical industry, particularly in the area of thromboembolic disease therapies, highlight his role as an influential inventor. His patents reflect a commitment to advancing medical science and improving patient outcomes.